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Background: This experimental study was designed to determine if Helicobacter spp. contribute to
benign gallbladder disease using polymerase chain reaction (PCR) methods.
Methods: Patients with benign gallbladder disease scheduled for elective cholecystectomy at New York
University Langone Medical Center were recruited from February to May 2008. Bile, gallbladder tissue
and gallstones were collected. DNA was isolated from these specimens and amplified via PCR using
C97F and C98R primers specific for Helicobacter spp. Appropriate positive and negative controls were
used. Products were analysed with agarose gel electrophoresis, sequenced and results aligned using
SEQUENCHER. Plasma was collected for detection of anti-Helicobacter pylori antibodies via enzyme-linked
immunosorbent assay.
Results: Of 36 patients, 12 patients' bile and/or tissue were positive for Helicobacter spp. by PCR.
Species were most homologous with H. pylori, although other Helicobacter spp. were suggested. Six of
12 patients demonstrated anti-Helicobacter antibodies in plasma, suggesting that the remaining six might
have demonstrated other species besides H. pylori. Four of six plasma samples with anti-Helicobacter
antibodies were anti-CagA (cytotoxin associated gene) negative.
Discussion: Helicobacter spp. can be detected in bile and gallbladder tissue of patients with benign
gallbladder disease. The contribution of these bacteria to the pathophysiology of gallbladder disease and
gallstone formation requires further study.
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Introduction
Bacterial colonization of tissue plays a critical role in human
health and disease.1 This interaction is well demonstrated by the
role of Helicobacter pylori in peptic ulcer disease.2 The recognition
of this interaction dramatically changed the management of
peptic ulcer disease and has led to a broader understanding of the
aetiology of benign and malignant disease of the stomach, duode-
num and oesophagus.2–6
Gallbladder disease has a significant impact on health care
in the USA. It is estimated that 750 000 cholecystectomies are
performed annually in the USA (http://www.ssat.com/cgi-bin/
chole7.cgi). Although the aetiology of gallbladder disease is mul-
tifactorial, bacteria are not traditionally thought to be a priming
factor for the development of gallstones or gallbladder inflam-
mation. In our own retrospective study of patients with gallblad-
der dysfunction, defined as a gallbladder ejection fraction of
35% on hepatobiliary iminodiacetic acid (HIDA) scan, 71%
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had pathological evidence of chronic cholecystitis and 40% of
those patients had no evidence of gallstones. Furthermore, we
found that 73.2% of 101 such patients also had gastro-
oesophageal reflux disease (GORD), whereas 58.4% had gastri-
tis.7 This observation raised the question of whether bacterial
colonization of the gallbladder may result in chronic inflamma-
tion similar to the association of H. pylori in chronic gastric
inflammation. It is generally accepted that biliary obstruction
and subsequent bile stasis can lead to bacterial overgrowth and
to the development of pigmented gallstones. Stewart and col-
leagues have demonstrated this and have also suggested that
11–20% of cholesterol gallstones, which had been thought to be
sterile, are colonized with bacteria.8,9 These data indicate that
bacteria may be important to the formation of all types of gall-
stones. Furthermore, recent evidence suggests that Helicobacter
spp., which are fastidious spiral or rod-shaped Gram negative
bacteria, can be found not only in gallstones10–12 but also in bile13
and gallbladder tissue of specimens demonstrating chronic
cholecystitis.13–15 This is particularly interesting in view of our
finding that 58% of patients with gallbladder dysfunction had
been diagnosed with gastritis, a disease associated with H. pylori
infection. Stathopoulos et al. reported an association between
gallstones and chronic gastritis.16 In their series, 14 of 19 patients
with symptomatic gallstones and moderate to marked gastritis
had evidence of H. pylori in the stomach, although the authors
did not investigate whether H. pylori could be detected in the
gallbladder.
The purpose of this study was to determine if bacteria, particu-
larly Helicobacter spp., play a role in benign gallbladder disease. To
our knowledge, no study has evaluated all three elements of the
gallbladder system (bile, gallbladder tissue and gallstones) in a
single cohort of patients for the presence of Helicobacter spp., as
we do here.
Materials and methods
Patients and specimen collection
During February–July 2008, 45 patients with benign gallbladder
disease undergoing elective cholecystectomy at New York Univer-
sity Langone Medical Center were recruited. Immediately follow-
ing gallbladder excision, the specimens were collected in a sterile
specimen cup. Tissue, bile and gallstones (when available) were
collected in a sterile manner and stored whole and unprocessed at
-800 °C until the time of experimentation. Both bile and tissue
samples were available for 36 of 45 (80%) patients; gallstones were
not available for analysis in five (13.9%) of these 36 patients.
Clinical history of antibiotic use within the past year, diagnosis
of upper gastrointestinal (UGI) disease and specimen patho-
logy (Table 1) were collected and stored in a Health Insurance
Portability and Accountability Act (HIPAA)-compliant database.
DNA extraction, polymerase chain reaction and
DNA sequencing
DNA was isolated from bile using the Qiamp DNA Stool Minikit
(Qiagen, Inc., Valencia, CA, USA) according to the company’s
Table 1 Clinical presentation of patients enrolled, including all patients and patients positive for Helicobacter by polymerase chain reaction
technique
Overall group Helicobacter spp.+
n = 36 n = 12
Bile + 5
Tissue + 4
Bile and tissue + 3
Median age, years 48.5 52.0
% female (median age) 52.8 (48.0) 50 (54.0)
% male (median age) 48.2 (50.5) 50 (50.5)
Took antibiotics within 1 year, n (%) 23 (63.9) 7 (58.3)
Unknown antibiotic use, n (%) 5 (13.9) 2 (16.7)
Pathology results
Chronic cholecystitis, n (%) 34 (94.4) 11 (91.7)
Cholesterolosis, n (%) 10 (27.7) 4 (33.3)
Clinical history, prior diagnoses
GORD, n (%) 16 (44.4) 5 (41.7)
Gastritis, n (%) 4 (11.1) 1 (8.3)
Unknown, n (%) 3 (8.3) 1 (8.3)
Helicobacter pylori serology
Anti-H. pylori, n (%) 10 (27.8) 6 (50)
Anti-CagA, n (%) 5 (13.9) 2 (16.7)
GORD, gastro-oesophageal reflux disease
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protocol. For DNA isolation from gallstones and tissue, the
DNeasy Blood and Tissue Kit (Qiagen, Inc.) was used.
Forward and reverse primers were selected to amplify a con-
served segment of the Helicobacter spp. 16s rRNA gene (C97F
[5′-GCTATGACGGGTATCC] and C98R [5′-GATTTTACC CCT
ACACCA]). An annealing temperature of 530 °C was used for 35
cycles. Polymerase chain reaction (PCR) was performed in dup-
licate on separate occasions for each DNA purified from the
samples. Products were analysed with agarose gel electrophoresis.
A patient sample was considered positive for Helicobacter spp. by
PCR method only when there was a positive result on two separate
occasions. If a sample demonstrated conflicting results within the
two runs (i.e. one positive and one negative result), the sample was
run a third time for a final result.
To confirm the presence of Helicobacter spp. DNA in bile and
tissue, PCR samples were sequenced (Macrogen Corp., Rockland,
MD, USA). The sequencher program was used for sequence
alignment. Species identification was performed using the blast
(Basic Local Alignment Search Tool) program from the National
Center for Biotechnology Information.
Results
Patients
Of 45 patients recruited to this study, 36 (median age 48.5 years,
range 24–79 years) had both bile and tissue specimens available
for analysis. Nineteen were women (median age 48.0 years, range
25–70 years) and 17 were men (median age 49.0 years, range
24–79 years) (Table 1). Thirty-four of 36 demonstrated biliary
colic or symptomatic gallstones, and two were diagnosed with
gallbladder-related pancreatitis. One of these two patients had a
common bile duct (CBD) and pancreatic duct (PD) stent placed
before his scheduled cholecystectomy. Sixteen of 36 (44.4%) had
a preoperative diagnosis of GORD, four (11.1%) were diagnosed
with gastritis and in three (8.3%) the diagnosis was unknown.
Identification by PCR of Helicobacter spp. in bile and
tissue specimens
Helicobacter spp. DNA was identified by PCR in eight of 36
(22.2%) bile samples and seven (19.4%) tissue samples for a total
of 12 patients, or 33.3% of the total group (Table 1, Fig. 1). Only
three patients demonstrated Helicobacter DNA in both bile and
tissue. None of the 31 gallstones available for analysis demon-
strated Helicobacter spp. DNA.
H. pylori identification by DNA sequencing in bile and
tissue specimens
Specimens positive for Helicobacter spp. DNA by PCR were con-
firmed by sequencing analysis in four bile and four tissue speci-
mens (from seven patients [19.4%]). Of the four bile and four
tissue specimens sequenced, blast results suggested that the
bacteria isolated for each sample was most consistent with H.
pylori. However, when evaluating results, other candidate bacteria
include Helicobacter acinonychis, Helicobacter pullorum, Helico-
bacter winghamensis, Helicobacter canadensis, Helicobacter bilis,
Helicobacter cinaedi and Helicobacter hepaticus because of the
high homology in DNA sequence. Only one patient was found to
have sequencing results demonstrating H. pylori in both bile and
tissue samples.
Overall assessment of Helicobacter in bile and tissue
of patients with benign gallbladder disease
The median age of the 12 patients with Helicobacter spp. in bile
and/or tissue was 52.0 years, which is similar to that of the total
group (Table 1). Six were women (50%, median age 54.0 years)
and six were men (50%, median age 50.5 years). Preoperative
diagnosis of UGI disease included GORD in five (41.7%), gastritis
in one (8.3%) and was unknown in one (8.3%). Only one patient
was tested by esophagogastroduodenoscopy (EGD) to evaluate
the presence of UGI disease.
Antibiotic use before surgery
Antibiotic use by patients within 1 year prior to cholecystectomy
was assessed as this could potentially alter the results. Data regard-
ing antibiotic use were available for 33 of 36 patients. Twelve of
36 (33.3%) had taken antibiotics within 1 month of surgery, 17
(47.2%) had not and four (11.1%) could not recall (Table 1). A
total of 23 of 36 (63.9%) had used antibiotics within 1 year of
surgery, five (13.9%) had not and five (13.9%) could not recall.
Antibiotics reported to have been used included clarithromycin,
azithromycin, metronidazole, amoxicillin, levofloxacin, ciprof-
loxacin and xifaxin. Of the 12 patients with PCR evidence for
Helicobacter, seven (58.3%) had taken antibiotics within 1 year of
surgery. Two of the 12 (16.7%) patients with PCR evidence did
not know whether they had used antibiotics in the year preceding
surgery.
Figure 1 Representative gel of bile samples after polymerase chain
reaction (PCR) amplification using Helicobacter-specific primers
C97F and C98R. Four water samples were used as a negative
control; HP26, a known Helicobacter pylori sample, was used in
duplicate as a positive control. In this gel, A, B, F and G were all
considered positive and I was considered indeterminate. G and I
were considered negative upon repeated PCR experiments. All other
samples were considered negative for Helicobacter spp.
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Pathology
Pathological evaluation of specimens from the 36 patients dem-
onstrated chronic cholecystitis in 34 patients (94.4%), cholestero-
losis in 10 (27.7%), acute on chronic cholecystitis in one (2.7%),
eosinophilic cholecystitis in one (2.7%), hyperplasia in one
(2.7%), lymphoid hyperplasia in one (2.7%), adenomyomatosis
in one (2.7%), and intestinal and pyloric gland metaplasia in
association with biliary intraepithelial neoplasia in one (2.7%).
Of 12 Helicobacter-positive patients, 11 (91.7%) had pathological
changes consistent with chronic cholecystitis and four (33.3%)
demonstrated cholesterolosis. One patient had acute on chronic
cholecystitis (8.3%), and one demonstrated tissue hyperplasia
(8.3%). Gallstone characterization was not recorded.
Anti-H. pylori and anti-CagA antibodies in plasma
Of the 36 patients studied, 34 had plasma available for enzyme-
linked immunosorbent assay (ELISA) analysis to evaluate for the
presence of H. pylori antibodies and anti-cytotoxin associated
gene (CagA) antibodies. Ten (27.8%) had detectable anti-H. pylori
antibodies and five of the 10 had detectable anti-CagA antibodies.
Of the 12 patients with Helicobacter spp., all had plasma samples
available for ELISA analysis. Six demonstrated anti-H. pylori anti-
bodies. This represents 60% of the 10 patients with these anti-
bodies in the whole group. Interestingly, four of these six (66.7%)
were anti-CagA- (Table 1).
Discussion
Evidence of Helicobacter spp. was found in 12 of 36 patients with
benign gallbladder disease, suggesting that Helicobacter spp. were
involved in 33.3% of patients studied. Only one patient whose
tissue was positive for Helicobacter had a history of biliary tract
manipulation, which may have resulted in direct inoculation of
bacteria in the biliary system. Preoperative diagnosis of GORD
(41.7%) or gastritis (8.3%) in the 12 positive patients was made by
clinical judgement, not by endoscopy or imaging studies, in all but
one patient. Therefore, no reliable conclusion can be drawn. The
female : male distribution did not differ from that seen overall in
the 12 patients and the age distribution was also similar. Of these
12 patients, six were seronegative for H. pylori, suggesting that
a different Helicobacter species was probably present (such as
H. acinonychis, H. pullorum, H. winghamensis, H. canadensis,
H. bilis, H. cinaedi or H. hepaticus as mentioned earlier).
Sequencing analysis suggests that the bacteria identified in this
group of seven patients were most probably H. pylori. Serology
results further support this in five of these seven patients as they
demonstrated anti-H. pylori antibodies in their serum. It is pos-
sible that the remaining two seronegative patients had different
Helicobacter spp. present in bile or tissue.13 Of the 12 patients who
were positive by PCR only, six had antibodies against H. pylori,
again suggesting that the other six had different Helicobacter spp.
present in bile or tissue.
We also determined whether seropositive patients had evidence
of exposure to CagA+ strains of H. pylori. CagA is a virulence
factor found in H. pylori that translocates into gastric epithelial
cells17 and is associated with increased inflammatory response
by gastric mucosal cells18,19 as well as an increased risk of gastric
adenocarcinoma.20 In this study, 66.7% of patients whose bile
or tissue were positive for Helicobacter spp. by PCR technique
only and who demonstrated anti-H. pylori antibodies were anti-
CagA-, whereas the remainder demonstrated evidence of infec-
tion with CagA+ strains. Although this did not reach statistical
significance, perhaps secondary to small sample size, this ques-
tions whether CagA- strains of H. pylori are more likely to colo-
nize or infect the gallbladder–biliary tract. This is particularly
interesting as the cagA genotype is thought to protect against more
severe forms of GORD, including the complication of Barrett’s
oesophagus.21,22 This observation supports our hypothesis that
benign gallbladder disease may be associated with GORD and
gastritis, and it may involve infection with CagA- strains of H.
pylori. Analysis of this hypothesis with a larger cohort of patients
should be performed.
None of the gallstone specimens were found to haveHelicobacter
DNA, although bacterial DNA was detected in the bile of some
patients. As Helicobacter spp. are fastidious organisms,
it may be that the gallstone environment is not appropriate
to support their growth. It is also possible that we did not detect
Helicobacter spp.because we did not analyse gallstone samples from
within the centre of the stones; instead, we took samples from the
outer surface of each gallstone. Stewart and colleagues’ founding
work demonstrated bacteria within the whole gallstone as each
gallstone studied was crushed before analysis.8,9 Other groups who
demonstratedHelicobacter spp. in gallstones took samples from the
centre of the stones or used the whole stone for analysis.10–12,23,24
Overall, 58.3% of 12 patients with Helicobacter spp. in bile
and/or tissue took antibiotics within 1 year prior to cholecystec-
tomy. Overall, 69.6% of patients analysed reported antibiotic use
within the previous year. In this preliminary study, we conclude
that antibiotic use probably did not affect the results as we were
able to detect Helicobacter spp. in patients who had used these
medications.
Pathologically, 91.7% of patients with Helicobacter DNA by
PCR had evidence of chronic cholecystitis. This does not differ
from findings for the whole group, in which 94.4% of patients
demonstrated evidence of chronic cholecystitis.
These results demonstrate that Helicobacter spp., particularly
H. pylori, can be detected in the bile and gallbladder tissue of
patients with benign gallbladder disease. The mechanism through
which these bacteria contribute to the pathophysiology of gall-
bladder disease, particularly gallstone formation, is unclear at this
time. This has been studied in more detail in a mouse model by
Maurer et al.,25,26 who suggest that Helicobacter spp. but not nec-
essarily H. pylori may contribute to benign gallbladder disease.
Based on our data, the paradigm of gallstone formation and the
contribution of Helicobacter spp. should be evaluated critically.
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